Last reviewed · How we verify

Double Umbilical Cord Blood Transplant

Medical College of Wisconsin · Phase 3 active Biologic

Double umbilical cord blood transplant involves infusing two units of umbilical cord blood-derived hematopoietic stem cells to reconstitute the patient's bone marrow and immune system.

Double umbilical cord blood transplant involves infusing two units of umbilical cord blood-derived hematopoietic stem cells to reconstitute the patient's bone marrow and immune system. Used for Acute leukemia in remission, Chronic leukemia, Myelodysplastic syndrome.

At a glance

Generic nameDouble Umbilical Cord Blood Transplant
SponsorMedical College of Wisconsin
Drug classCell therapy / Hematopoietic stem cell transplant
ModalityBiologic
Therapeutic areaOncology / Hematology
PhasePhase 3

Mechanism of action

This procedure uses stem cells from two separate umbilical cord blood units to overcome the limited cell dose from a single unit, allowing successful engraftment in adult patients. The dual units provide sufficient hematopoietic progenitor cells to restore blood cell production and immune function in patients with hematologic malignancies or bone marrow disorders after myeloablative conditioning.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: